Oppenheimer Asset Management Inc. Abcam PLC Transaction History

Oppenheimer Asset Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$21.54 - $24.41 $547,029 - $619,916	-25,396 Reduced 57.23%	18,981 $429,000
Q2 2023 Aug 02, 2023	BUY	$12.62 - $24.47 $25,946 - $50,310	2,056 Added 4.86%	44,377 $1.09 Million
Q1 2023 May 10, 2023	BUY	$12.98 - $17.1 $90,055 - $118,639	6,938 Added 19.61%	42,321 $569,000
Q4 2022 Feb 06, 2023	SELL	$13.92 - $17.0 $904 - $1,105	-65 Reduced 0.18%	35,383 $550,000
Q3 2022 Nov 14, 2022	SELL	$13.36 - $16.75 $516,364 - $647,387	-38,650 Reduced 52.16%	35,448 $532,000
Q2 2022 Aug 08, 2022	BUY	$12.69 - $19.25 $465,126 - $705,570	36,653 Added 97.88%	74,098 $1.07 Million
Q1 2022 May 12, 2022	BUY	$15.5 - $23.89 $12,245 - $18,873	790 Added 2.16%	37,445 $685,000
Q4 2021 Feb 02, 2022	BUY	$20.04 - $23.84 $14,388 - $17,117	718 Added 2.0%	36,655 $864,000
Q3 2021 Nov 12, 2021	BUY	$17.38 - $21.54 $18,770 - $23,263	1,080 Added 3.1%	35,937 $728,000
Q2 2021 Aug 03, 2021	BUY	$18.47 - $22.11 $643,808 - $770,688	34,857 New	34,857 $664,000

1.03M

Ticker ABCM
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 229,044,992
Description
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.